This article is more than 5 years old. Information may no longer be current.
CMS grants NTAP to Defitelio for treatment of hepatic VOD
Click Here to Manage Email Alerts
Jazz Pharmaceuticals announced that CMS has granted a New Technology Add-on Payment for Defitelio, according to a press release.
“CMS’ decision to grant NTAP designation for Defitelio recognizes the significant therapeutic advance of this first-of-its kind treatment for children and adults with veno-occlusive disease with renal or pulmonary dysfunction following stem-cell transplantation,” Mike Miller, senior vice president and U.S. commercial lead at Jazz Pharmaceuticals, said in the release. “The NTAP designation also underscores the clinical value of Defitelio, which offers a potentially curative intervention for patients with veno-occlusive disease following hematopoietic stem-cell transplantation, which may save lives with a single course of therapy.”
Mike Miller
In March, the FDA approved Defitelio (defibrotide sodium) for the treatment of patients with hepatic veno-occlusive disease — also called sinusoidal obstruction syndrome — with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
NTAP — which was introduced by Congress in 2001 — will provide reimbursement to hospitals paid under the Medicare Hospital Inpatient Prospective Payment System and will also support Medicare patients’ access to Defitelio. The NTAP payment for Defitelio has been established at $75,900, which is effective 2017.
“Before Defitelio, patients had no options for this rare and often deadly complication of stem-cell transplantation,” Miller said. “Importantly, the NTAP payment will ultimately help improve Medicare beneficiaries’ access to Defitelio in the inpatient Prospective Payment System hospital setting.” – by Will Offit
Disclosure: Miller is an employee of Jazz Pharmaceuticals.